Rabbit Anti-T Cell Globulin in Allogeneic Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 6, 2015, Pages 959-970

  Storek, Jan ^a   Mohty, Mohamad ^b   Boelens, Jaap Jan ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antithymocyte globulin; Graft versus host disease; Hematopoietic cell transplantation

Indexed keywords

THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MYELOABLATIVE AGENT;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CHILD; DRUG FORMULATION; GRAFT VERSUS HOST REACTION; HUMAN; INFECTION; MYELOABLATIVE CONDITIONING; NONHUMAN; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; RABBIT; RELAPSE; REVIEW; SURVIVAL RATE; VIRUS INFECTION; ALLOTRANSPLANTATION; ANIMAL; EPSTEIN BARR VIRUS; EPSTEIN-BARR VIRUS INFECTIONS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; MORTALITY; PATHOLOGY; PROCEDURES; QUALITY OF LIFE; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING;

ADULT; ANIMALS; ANTILYMPHOCYTE SERUM; EPSTEIN-BARR VIRUS INFECTIONS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYELOABLATIVE AGONISTS; QUALITY OF LIFE; RABBITS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84939222762     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.11.676     Document Type: Review

References (105)

1. Bacigalupo A., Van Lint M.T., Occhini D., et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991, 77:1423-1428.
2. Storb R., Deeg H.J., Pepe M., et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial. Blood 1989, 73:1729-1734.
3. Locatelli F., Zecca M., Rondelli R., et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: Results of a randomized trial. Blood 2000, 95:1572-1579.
4. Wagner J.E., Thompson J.S., Carter S.L., et al. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): A multi-centre, randomised phase II-III trial. Lancet 2005, 366:733-741.
5. Marmont A.M., Horowitz M.M., Gale R.P., et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991, 78:2120-2130.
6. Scheinberg P., Nunez O., Weinstein B., et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011, 365:430-438.
7. Dufour C., Svahn J., Bacigalupo A., et al. Front-line immunosuppressive treatment of acquired aplastic anemia. Bone Marrow Transplant 2013, 48:174-177.
8. Champlin R.E., Perez W.S., Passweg J.R., et al. Bone marrow transplantation for severe aplastic anemia: A randomized controlled study of conditioning regimens. Blood 2007, 109:4582-4585.
9. Doney K.C., Weiden P.L., Storb R., Thomas E.D. Failure of early administration of antithymocyte globulin to lessen graft-versus-host disease in human allogeneic marrow transplant recipients. Transplantation 1981, 31:141-143.
10. Hagen P., Wagner J.E., DeFor T.E., et al. The effect of equine antithymocyte globulin on the outcomes of reduced intensity conditioning for AML. Bone Marrow Transplant 2014, 49:1498-1504.
11. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007, 21:1387-1394.
12. Leitner J., Grabmeier-Pfistershammer K., Majdic O., et al. Interaction of antithymocyte globulins with dendritic cell antigens. Am J Transplant 2011, 11:138-145.
13. Shenton B.K., White M.D., Bell A.E., et al. The paradox of ATG monitoring in renal transplantation. Transplant Proc 1994, 26:3177-3180.
14. Popow I., Leitner J., Majdic O., et al. Assessment of batch to batch variation in polyclonal antithymocyte globulin preparations. Transplantation 2012, 93:32-40.
15. Naujokat C., Berges C., Fuchs D., et al. Antithymocyte globulins suppress dendritic cell function by multiple mechanisms. Transplantation 2007, 83:485-497.
16. Ruutu T., Gratwohl A., de Witte T., et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant 2014, 49:168-173.
17. Van Lint M.T., Milone G., Leotta S., et al. Treatment of acute graft-versus-host disease with prednisolone: Significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 2006, 107:4177-4181.
18. Jamani K., Russell J.A., Daly A., et al. Prognosis of grade 3-4 acute GVHD continues to be dismal. Bone Marrow Transplant 2013, 48:1359-1361.
19. Yu Z.P., Ding J.H., Wu F., et al. Quality of life of patients after allogeneic hematopoietic stem cell transplantation with antihuman thymocyte globulin. Biol Blood Marrow Transplant 2012, 18:593-599.
20. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001, 98:2942-2947.
21. Walker I., Schultz K.R., Toze C.L., et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. American Society of Hematology Annual Meeting. Blood 2014, 124. Abstract 38.
22. Ravinet A., Cabrespine A., Socie G., et al. Impact of antithymocyte globulins on patient outcome after myeloablative bone marrow stem cell transplantation from HLA 10/10-matched unrelated donor: A report from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC) American Society of Hematology Annual Meeting. Blood 2014, 124. Abstract 1218.
23. Haidinger M., Geyeregger R., Poglitsch M., et al. Antithymocyte globulin impairs T-cell/antigen-presenting cell interaction: Disruption of immunological synapse and conjugate formation. Transplantation 2007, 84:117-121.
24. Feng X., Kajigaya S., Solomou E.E., et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood 2008, 111:3675-3683.
25. Shimony O., Nagler A., Gellman Y.N., et al. Anti-T lymphocyte globulin (ATG) induces generation of regulatory T cells, at least part of them express activated CD44. J Clin Immunol 2012, 32:173-188.
26. LaCorcia G., Swistak M., Lawendowski C., et al. Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppressive capabilities beyond cell depletion. Transplantation 2009, 87:966-974.
27. Mahmud D., Nicolini B., van den Dries L., et al. Human CD4(+)CD25(+) cells in combination with CD34(+) cells and thymoglobulin to prevent anti-hematopoietic stem cell T cell alloreactivity. Biol Blood Marrow Transplant 2011, 17:61-68.
28. Monti P., Allavena P., Di Carlo V., Piemonti L. Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol 2003, 3:189-196.
29. Fang L., Fehse B., Engel M., et al. Antithymocyte globulin induces ex vivo and in vivo depletion of myeloid and plasmacytoid dendritic cells. Transplantation 2005, 79:369-371.
30. Gillet-Hladky S., de Carvalho C.M., Bernaud J., et al. Rabbit antithymocyte globulin inhibits monocyte-derived dendritic cells maturation in vitro and polarizes monocyte-derived dendritic cells towards tolerogenic dendritic cells expressing indoleamine 2,3-dioxygenase. Transplantation 2006, 82:965-974.
31. Ruzek M.C., Neff K.S., Luong M., et al. In vivo characterization of rabbit anti-mouse thymocyte globulin: A surrogate for rabbit anti-human thymocyte globulin. Transplantation 2009, 88:170-179.
32. Xystrakis E., Bernard I., Dejean A.S., et al. Alloreactive CD4 T lymphocytes responsible for acute and chronic graft-versus-host disease are contained within the CD45RChigh but not the CD45RClow subset. Eur J Immunol 2004, 34:408-417.
33. Bosch M., Dhadda M., Hoegh-Petersen M., et al. Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy 2012, 14:1258-1275.
34. Fehse N., Fehse B., Kroger N., et al. Influence of anti-thymocyte globulin as part of the conditioning regimen on immune reconstitution following matched related bone marrow transplantation. J Hematother Stem Cell Res 2003, 12:237-242.
35. Na I.K., Wittenbecher F., Dziubianau M., et al. Rabbit antithymocyte globulin (thymoglobulin) impairs the thymic output of both conventional and regulatory CD4+ T cells after allogeneic hematopoietic stem cell transplantation in adult patients. Haematologica 2013, 98:23-30.
36. Ayuk F.A., Atassi N., Schuch G., et al. Complement-dependent and complement-independent cytotoxicity of polyclonal antithymocyte globulins in chronic lymphocytic leukemia. Leuk Res 2008, 32:1200-1206.
37. Grullich C., Ziegler C., Finke J. Rabbit anti T-lymphocyte globulin induces apoptosis in peripheral blood mononuclear cell compartments and leukemia cells, while hematopoetic stem cells are apoptosis resistant. Biol Blood Marrow Transplant 2009, 15:173-182.
38. Yoshimi A., Ito M., Kojima S. Leukemic cell death induced by antithymocyte globulin. Leuk Res 2005, 29:821-827.
39. Ayuk F., Maywald N., Hannemann S., et al. Comparison of the cytotoxicity of 4 preparations of anti-T-cell globulins in various hematological malignancies. Anticancer Res 2009, 29:1355-1360.
40. Liu H., Qin Y., Wang X., et al. Polyclonal rabbit antithymocyte globulin induces apoptosis and has cytotoxic effects on human leukemic cells. Clin Lymphoma Myeloma Leuk 2012, 12:345-354.
41. Zander A.R., Kroger N., Schleuning M., et al. ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML). Bone Marrow Transplant 2003, 32:355-361.
42. Schattenberg A., van der Meer A., Preijers F., et al. Addition of ATG to the conditioning regimen is a major determinant for outcome after transplantation with partially lymphocyte-depleted grafts from voluntary unrelated donors. Bone Marrow Transplant 2004, 33:1115-1121.
43. Crocchiolo R., Esterni B., Castagna L., et al. Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases. Cancer 2013, 119:986-992.
44. Remberger M., Ringden O., Hagglund H., et al. A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors. Clin Transplant 2013, 27:E368-E374.
45. Wolschke C., Zabelina T., Ayuk F., et al. Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation. Bone Marrow Transplant 2014, 49:126-130.
46. Wang Y., Fu H.X., Liu D.H., et al. Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: A randomized trial. Bone Marrow Transplant 2014, 49:426-433.
47. Remberger M., Svahn B.M., Mattsson J., Ringden O. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 2004, 78:122-127.
48. Hamadani M., Blum W., Phillips G., et al. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2009, 15:1422-1430.
49. Finke J., Bethge W.A., Schmoor C., et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: A randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009, 10:855-864.
50. Podgorny P.J., Ugarte-Torres A., Liu Y., et al. High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder. Biol Blood Marrow Transplant 2010, 16:915-926.
51. Hoegh-Petersen M., Amin M.A., Liu Y., et al. Anti-thymocyte globulins capable of binding to T and B cells reduce graft-vs-host disease without increasing relapse. Bone Marrow Transplant 2013, 48:105-114.
52. Milano F., Au M.A., Boeckh M.J., et al. Evaluating the impact of antithymocyte globulin on lung function at 1 year after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:703-709.
53. Bollard C.M., Rooney C.M., Heslop H.E. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol 2012, 9:510-519.
54. Wagner H.J., Cheng Y.C., Huls M.H., et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004, 103:3979-3981.
55. Charpentier B., Rostaing L., Berthoux F., et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation 2003, 75:844-851.
56. Thibaudin D., Alamartine E., de Filippis J.P., et al. Advantage of antithymocyte globulin induction in sensitized kidney recipients: A randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol Dial Transplant 1998, 13:711-715.
57. Mourad G., Garrigue V., Squifflet J.P., et al. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation 2001, 72:1050-1055.
58. Wang W., Yin H., Li X.B., et al. A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin. Chin Med J (Engl) 2012, 125:1135-1140.
59. Buchler M., Hurault de Ligny B., Madec C., et al. Induction therapy by anti-thymocyte globulin (rabbit) in renal transplantation: A 1-yr follow-up of safety and efficacy. Clin Transplant 2003, 17:539-545.
60. Bonifazi F., Solano C., Wolschke C., et al. Prevention of chronic GvHD after HLA-identical sibling peripheral hematopoietic stem cell transplantation with or without anti-lymphocyte globulin (ATG). Results from a prospective, multicenter randomized phase III trial (ATG family study). American Society of Hematology Annual Meeting. Blood 2014, 124. Abstract 37.
61. Soiffer R.J., Lerademacher J., Ho V., et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011, 117:6963-6970.
62. Devillier R., Labopin M., Chevalier P., et al. Higher doses of antithymocyte globulin (ATG) increase the risk of relapse in acute myeloid leukemia (AML) patients undergoing matched related donor allogeneic transplantation in first complete remission (CR1): an analysis from the Acute Leukemia Working Party of EBMT. American Society of Hematology Annual Meeting. Blood 2014, 124. Abstract 729.
63. Russell J.A., Turner A.R., Larratt L., et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: A matched pair analysis. Biol Blood Marrow Transplant 2007, 13:299-306.
64. Bacigalupo A., Lamparelli T., Barisione G., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: Long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006, 12:560-565.
65. Ljungman P., Hakki M., Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin North Am 2010, 24:319-337.
66. Ugarte-Torres A., Hoegh-Petersen M., Liu Y., et al. Donor serostatus has an impact on cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2011, 17:574-585.
67. Kroger N., Zabelina T., Kruger W., et al. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin. Br J Haematol 2001, 113:1060-1071.
68. Matthes-Martin S., Lion T., Aberle S.W., et al. Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality. Bone Marrow Transplant 2003, 31:803-808.
69. Ringden O., Schaffer M., Le Blanc K., et al. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?. Biol Blood Marrow Transplant 2004, 10:128-134.
70. Chalandon Y., Degermann S., Villard J., et al. Pretransplantation CMV-specific T cells protect recipients of T-cell-depleted grafts against CMV-related complications. Blood 2006, 107:389-396.
71. Flowers M.E., Inamoto Y., Carpenter P.A., et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011, 117:3214-3219.
72. Lim ABM, Beligaswatte A, Collins M, et al. Risk factors for acute and chronic GVHD in allogeneic transplant recipients receiving Thymoglobulin GVHD prophylaxis. Bone Marrow Transplant; in press.
73. Lim A.B.M., Storek J., Beligaswatte A., et al. High donor and recipient age are not risk factors for chronic graft-versus-host disease in the setting of anti-thymocyte globulin-conditioned hematopoietic stem cell transplantation. Tandem Blood and Marrow Transplant Annual Meeting 2013, S334. Salt Lake City, Utah. T. BoBaM (Ed.).
74. Bacigalupo A., Lamparelli T., Milone G., et al. Pre-emptive treatment of acute GVHD: A randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants. Bone Marrow Transplant 2010, 45:385-391.
75. Levine J.E., Paczesny S., Sarantopoulos S. Clinical applications for biomarkers of acute and chronic graft-versus-host disease. Biol Blood Marrow Transplant 2012, 18:S116-124.
76. Vander Lugt M.T., Braun T.M., Hanash S., et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med 2013, 369:529-539.
77. Call S.K., Kasow K.A., Barfield R., et al. Total and active rabbit antithymocyte globulin (rATG;Thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant 2009, 15:274-278.
78. Seidel M.G., Fritsch G., Matthes-Martin S., et al. Antithymocyte globulin pharmacokinetics in pediatric patients after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 2005, 27:532-536.
79. Admiraal R., Jol-van der Zijde J.C.M., van Kesteren C., et al. Exposure of thymoglobulin is associated with overall survival in children receiving allogeneic HCT: Towards individualized dosing to improve survival. Biol Blood Marrow Transplant 2014, 20(Suppl 1):S76-S78.
80. Locatelli F., Bernardo M.E., Rognoni C. Results of an open-label, prospective, randomized clinical trial on two different dosages of rabbit anti-thymocyte globuline in children with hematological malignancies given allogeneic HCT from an unrelated donor. European Blood and Marrow Transplant Annual Meeting. Milan, Italy. Bone Marrow Transplant 2014, 49(Suppl 1):S1.
81. Cohen G., Carter S.L., Weinberg K.I., et al. Antigen-specific T-lymphocyte function after cord blood transplantation. Biol Blood Marrow Transplant 2006, 12:1335-1342.
82. Chiesa R., Gilmour K., Qasim W., et al. Omission of in vivo T-cell depletion promotes rapid expansion of naive CD4+ cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant. Br J Haematol 2012, 156:656-666.
83. Lindemans C.A., Chiesa R., Amrolia P.J., et al. Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome. Blood 2014, 123:126-132.
84. Bartelink I.H., van Reij E.M., Gerhardt C.E., et al. Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity. Biol Blood Marrow Transplant 2014, 20:345-353.
85. Remberger M., Persson M., Mattsson J., et al. Effects of different serum-levels of ATG after unrelated donor umbilical cord blood transplantation. Transpl Immunol 2012, 27:59-62.
86. Pascal L., Mohty M., Ruggeri A., et al. Impact of rabbit ATG-containing myeloablative conditioning regimens on the outcome of patients undergoing unrelated single-unit cord blood transplantation for hematological malignancies. Bone Marrow Transplant 2014, [Epub ahead of print]. doi:10.1038/bmt.2014.216.
87. Jol-van der Zijde C.M., Bredius R.G., Jansen-Hoogendijk A.M., et al. IgG antibodies to ATG early after pediatric hematopoietic SCT increase the risk of acute GVHD. Bone Marrow Transplant 2012, 47:360-368.
88. Schleuning M., Gunther W., Tischer J., et al. Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML. Bone Marrow Transplant 2003, 32:243-250.
89. Waller E.K., Langston A.A., Lonial S., et al. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 2003, 9:460-471.
90. Kakhniashvili I., Filicko J., Kraft W.K., Flomenberg N. Heterogeneous clearance of antithymocyte globulin after CD34+-selected allogeneic hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 2005, 11:609-618.
91. Schatorje E.J., Gemen E.F., Driessen G.J., et al. Paediatric reference values for the peripheral T cell compartment. Scand J Immunol 2012, 75:436-444.
92. Admiraal R, van Kesteren C, Jol van der Zijde CM, et al. Population pharmacokinetic modeling of thymoglobulin in children receiving allogeneic-hematopoietic cell transplantation: Towards improved survival through individualized dosing. Clin Pharmacokinetics, 2014;in press.
93. Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: Efficacy and side effects. Bone Marrow Transplant 2005, 35:225-231.
94. Socie G., Schmoor C., Bethge W.A., et al. Chronic graft-versus-host disease: Long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011, 117:6375-6382.
95. Basara N., Baurmann H., Kolbe K., et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: Results from the multicenter German cooperative study group. Bone Marrow Transplant 2005, 35:1011-1018.
96. Mohty M., Labopin M., Balere M.L., et al. Antithymocyte globulins and chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: A report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Leukemia 2010, 24:1867-1874.
97. Baron F., Labopin M., Niederwieser D., et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia 2012, 26:2462-2468.
98. Bonifazi F., Bandini G., Arpinati M., et al. Intensification of GVHD prophylaxis with low-dose ATG-F before allogeneic PBSC transplantation from HLA-identical siblings in adult patients with hematological malignancies: Results from a retrospective analysis. Bone Marrow Transplant 2012, 47:1105-1111.
99. Dulery R., Mohty M., Duhamel A., et al. Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: A study from the French Society of Bone Marrow Transplantation and Cellular Therapy. Biol Blood Marrow Transplant 2014, 20:646-654.
100. Baron F., Labopin M., Blaise D., et al. Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2014, 49:389-396.
101. Remberger M., Sundberg B. Low serum levels of total rabbit-IgG is associated with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation: Results from a prospective study. Biol Blood Marrow Transplant 2009, 15:996-999.
102. Chawla S., Dharmani-Khan P., Liu Y., et al. High serum level of antithymocyte globulin immediately before graft infusion is associated with a low likelihood of chronic, but not acute, graft-versus-host disease. Biol Blood Marrow Transplant 2014, 20:1156-1162.
103. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: Working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
104. Sormani M.P., Oneto R., Bruno B., et al. A revised day +7 predictive score for transplant-related mortality: Serum cholinesterase, total protein, blood urea nitrogen, [gamma] glutamyl transferase, donor type and cell dose. Bone Marrow Transplant 2003, 32:205-211.
105. Pratt L.M., Liu Y., Ugarte-Torres A., et al. IL15 levels on day 7 after hematopoietic cell transplantation predict chronic GVHD. Bone Marrow Transplant 2013, 48:722-728.